# A Phase 2 Study of ABSK043 Combined With Osimertinib

Source: https://onco.cc/trials/nct07710612/  
OnCo record `nct07710612` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of osimertinib in lung cancer, run by Abbisko Therapeutics Co, Ltd, not yet recruiting.

## Summary

A Phase 2 Study of ABSK043 Combined With Osimertinib is a phase 2, interventional study registered as NCT07710612 by Abbisko Therapeutics Co, Ltd, with a registry enrolment figure of 72 participants, started 2026-08-31 and due to reach its primary completion in 2029-12-31. Interventions recorded: ABSK043 in combination with Osimertinib. Conditions listed: Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive. Primary outcome: - Incidence of dose-limiting toxicity (DLT); Adverse events(AEs); Serious adverse events (SAEs). Lung eligibility wording from the registry: "NSCLC with a mixed histology is eligible, if adenocarcinoma is the predominant histology". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07710612
- Phase: 2
- Setting: A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of ABSK043 Combined With Osimertinib in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: Abbisko Therapeutics Co, Ltd
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT07710612: https://clinicaltrials.gov/study/NCT07710612

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [Abbisko Therapeutics](https://onco.cc/companies/abbisko/), [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07710612.json